NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE
1 - ORGANIZATION AND BASIS OF PRESENTATION
SmartMetric,
Inc. (the “Company” or “SmartMetric”) was incorporated in the State of Nevada on December 18, 2002. SmartMetric’s
main product is a fingerprint sensor-activated card with a finger sensor onboard the card and a built-in rechargeable battery for portable
biometric identification. This card may be referred to as a biometric card or the SmartMetric Biometric Datacard. SmartMetric has
completed development of its card along with pre-mass manufacturing cards but has not yet begun to mass manufacture the biometric fingerprint
activated cards.
The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting
principles for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include
all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion
of management of the Company, the accompanying unaudited financial statements contain all the adjustments (which are of a normal recurring
nature) necessary for a fair presentation. Operating results for the three and six months ended December 31, 2021 are not necessarily
indicative of the results that may be expected for the year ending June 30, 2022. For further information, refer to the financial statements
and the footnotes thereto contained in the Company’s Annual Report on Form 10-K for the year ended June 30, 2021, as filed with
the Securities and Exchange Commission on October 12, 2021. The consolidated balance sheet as of June 30, 2021, has been derived from
the audited financial statements at that date, but does not include all the information and footnotes required by US GAAP for complete
financial statements.
Going
Concern
As
shown in the accompanying condensed consolidated financial statements the Company has sustained recurring losses of $1,419,543 for
the six months ended December 31, 2021 and has an accumulated deficit of $30,283,710 at December 31, 2021.
These
conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date of this
filing. The financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts
or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
The COVID-19 has had an impact on SmartMetric’s final card production. While the delays are due to supply line disruption, the
Company is confident that these delays will be short-lived based on advice from our manufacturing partners, manufacturing alternatives
and alternative supply lines that are being put into place by the Company.
Management
believes that the Company’s capital requirements will depend on many factors. These factors include product marketing and distribution.
The management plans include equity sales and borrowing in order to fund the operations.
There
are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations
to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have
to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be
on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations.
In
December 2019, an outbreak of a novel strain of coronavirus originated in Wuhan, China (“COVID-19”) and has since spread
worldwide, including to the Unites States, posing public health risks that have reached pandemic proportions (the “COVID-19 Pandemic”).
The COVID-19 Pandemic poses a threat to the health and economic wellbeing of our employees, customers and vendors. Like most businesses
world-wide, the COVID-19 Pandemic has impacted the Company financially; delaying the beginning of production.
Principles
of Consolidation
The
condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, SmartMetric Australia
Pty. Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation.
NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Use
of Estimates
The
preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting
period. On an ongoing basis, the Company evaluates its estimates, including, but not limited to, those related to income taxes and
contingencies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be
reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities
that are not readily apparent from other sources. Actual results could differ from those estimates.
Research
and Development
Research
and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for
electronics design and engineering, software design and engineering, component sourcing, component engineering, manufacturing, product
trials, compensation and consulting costs.
Recent
Accounting Pronouncements
The
Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s
results of operations, financial position or cash flow.
Loss
Per Share of Common Stock
In
accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable
to common stockholders by the weighted average number of common shares outstanding during the period. Basic net loss per share excludes
the dilutive effect of stock options or warrants and convertible notes. Diluted net earnings (loss) per common share is determined using
the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents,
consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the
weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.
As of December 31, 2021 and 2020, 69,163,518 and 112,170,182 dilutive shares were excluded from the calculation of diluted
loss per common share, with all dilutive shares being common stock warrants at December 31, 2021 and 2020, as their effect would be anti-dilutive.
Stock-Based
Compensation
The
Company records stock-based compensation in accordance with ASC 718, Compensation – Stock Compensation and ASC
505-50, Equity-Based Payments to Non-Employees. All transactions in which goods or services are the consideration received
for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the
equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services
received as consideration are measured and recognized based on the fair value of the equity instruments issued and are recognized over
the employees required service period, which is generally the vesting period.
NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Fair
value of financial instruments
The
Company measures fair value in accordance with ASC 820 - Fair Value Measurements. ASC 820 defines fair value and establishes a three-level
valuation hierarchy for disclosures of fair value measurements. ASC 820 establishes a framework for measuring fair value in generally
accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair
value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques
used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted)
in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value
hierarchy defined by ASC 820 are:
Level
1 - Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
Level
2 - Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset
or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated
life.
Level
3 - Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability
at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to
the model. Valuation of instruments includes unobservable inputs to the valuation methodology that are significant to the measurement
of fair value of assets or liabilities.
As
defined by ASC 820, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction
between willing parties, other than in a forced or liquidation sale, which was further clarified as the price that would be received
to sell an asset or paid to transfer a liability (“an exit price”) in an orderly transaction between market participants
at the measurement date.
The
reported fair values for financial instruments that use Level 2 and Level 3 inputs to determine fair value are based on a variety of
factors and assumptions. Accordingly, certain fair values may not represent actual values of the Company’s financial instruments
that could have been realized as of December 31, 2021 or that will be recognized in the future, and do not include expenses that could
be incurred in an actual settlement. The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts
receivable, receivables from related parties, prepaid expenses and other, accounts payable, accrued liabilities, and related party and
third-party notes payables approximate fair value due to their relatively short maturities. The Company’s notes payable to related
parties approximates the fair value of such instrument based upon management’s best estimate of terms that would be available to
the Company for similar financial arrangements at December 31, 2021.
NOTE
3 - PREPAID EXPENSES
Prepaid
expenses represent the unexpired terms of various consulting agreements as well as advance rental payments. Prepaid expenses at December
31, 2021 were $5,000.
NOTE
4 - COMMITMENTS AND CONTINGENCIES
Lease
Agreement
The
Company’s main office is in Las Vegas, Nevada. Rent expense under all leases for the three months ended December 31, 2021 and 2020
was $1,590 and $1,666 respectively. The Company maintains only one office. This office is in Las Vegas, NV and is a month-to-month
lease.
NOTE
4 - COMMITMENTS AND CONTINGENCIES (CONTINUED)
Related
Party Transactions
As
of December 31, 2021 and 2020, the Company has accrued the amounts of $737,642 and $744,115, respectively, as deferred Officer’s
salary for the difference between the president’s annual salary and the amounts paid.
As
a result of shareholder loans and deferred officer salary, the Company has accrued a balance of $227,665 and $175,664 as interest
payable as of December 31, 2021 and 2020.
On
September 11, 2017, we received a license to certain patents from Chaya Hendrick, our founder and CEO, related to our technologies until
the expiration of the patents. As consideration, we issued Chaya Hendrick, or her assigns, (i) 200,000 shares of Series B Convertible
Preferred Stock, (ii) a royalty equal to 5% of gross revenues derived from products sold related to the patents, and (iii) certain minimum
required payments beginning at $50,000 and doubling each year thereafter. The Series B Preferred Stock may be converted at the election
of holder on a basis for 50 common shares for each preferred share at any time or an aggregate of 10,000,000 common shares in exchange
for all 200,000 shares of Series B Convertible Preferred Stock.
Our
CEO maintains an employment agreement that stipulates a $190,000 annual salary. This agreement is in effect until mutual agreement
between its CEO and the Company to terminate.
Litigation
From
time to time we may be a defendant or plaintiff in various legal proceedings arising in the normal course of our business. As of the
date of this Quarterly Report, there are no material pending legal or governmental proceedings relating to us or properties to which
we are a party, and, to our knowledge, there are no material proceedings to which any of our directors, executive officers or affiliates
are a party adverse to us or which have a material interest adverse to us.
NOTE
5 - DEBT
On
April 17, 2020, we received funds under the Paycheck Protection Program, a part of the CARES Act. The loan is serviced by Chase Bank,
and the application for these funds required us to, in good faith, certify that the current economic uncertainty made the loan necessary
to support our ongoing operations. We used the funds for payroll and related costs. The receipt of these funds, and the forgiveness of
the loan attendant to these funds, was dependent on our ability to adhere to the forgiveness criteria. The loan bears interest at a rate
of 0.98% per annum and had a maturity date of April 6, 2022, with the first payment being deferred until April 17, 2021. Under the terms
of the PPP, certain amounts may be forgiven if they are used in accordance with the CARES Act. The Company applied for forgiveness of
this loan as of October 2021 and forgiveness was granted by the Small Business Administration. Therefore, the loan is considered paid
in full.
On
March 5, 2020, the Company issued a $35,000 10% convertible note to an investor, GHS Investments, LLC, in relation to an equity financing agreement (see
Note 6). The note was due on December 5, 2020 and is convertible at a rate of $0.0175 per share which resulted in a discount from
the beneficial conversion feature totaling $5,000. During the year ended June 30, 2020, $2,127 of the debt discount was amortized.
For the three month period ended December 31, 2021, $3,804 of the debt discount was amortized. As of December 31, 2021, all $5,000 of
the debt discount was fully amortized and the note was at its full amount of $35,000. As of December 31, 2021, the note has not been
paid and currently is in default. The default conversion rate is convertible at a variable rate. Accordingly, the Company concluded there
is an embedded derivative which was required to be bifurcated and accounted for as a derivative liability. The Company chose to use the
Black Scholes model to calculate the derivative liability. The assumptions in the derivative liability calculation included the price
of the Company’s common stock of $0.0070 at the valuation date, term of zero, a risk free rate of between $0.0010 and $0.0011 and
a volatility rate of between 337% and 341%.
NOTE
5 - DEBT (CONTINUED)
On
July 23, 2021, the Company entered into a Securities Purchase Agreement with AJB Capital Investments, LLC (the
“Investor”) with respect to the sale and issuance of: (i) a commitment fee in the amount of $250,000 in
the form of 12,500,000 shares
of the Company’s common stock (the “Commitment Fee Shares”), (ii) a promissory note in the aggregate principal
amount of $300,000
(the “Note”), (iii) Common Stock Purchase Warrants to purchase up to an aggregate of 10,000,000 shares
of the common stock (the “Warrants”), and (iv) 5,000 shares
of the Company’s Series D Convertible Preferred Stock. The Note and Warrants were issued on July 23, 2021. The Commitment Fee
Shares were issued at a value of $250,000, the Note was issued in a principal amount of $300,000 for
a purchase price of $270,000,
resulting in an original issue discount of $30,000; the Warrants were issued, with an initial exercise price of $0.05 per
share, subject to adjustment; and 5,000 Series
D Shares were issued to be converted into the shares of common stock of the Company solely in the event of default under the
Purchase Agreement. The aggregate cash subscription amount received by the Company from the Investor for the issuance of the
Commitment Fee Shares, Note and Warrants was $253,000,
due to a reduction in the $270,000 purchase
price as a result of broker, legal, and transaction fees.
NOTE
6 - STOCKHOLDERS’ DEFICIT
Preferred
Stock
Series
B Convertible Preferred Stock
On
December 11, 2009, the Company filed a Certificate of Designation with the State of Nevada, to designate 500,000 shares of
preferred stock as Series B Convertible Preferred Stock (“Series B Convertible Preferred Stock”). Effective November 5, 2014,
the number of shares designated as Series B Convertible Preferred Stock was increased to 5,000,000 shares.
The
Company issued 200,000 shares of Series B Convertible Preferred Stock upon its inception in 2004.
In
October 2015, the Company issued 200,000 shares of Series B Convertible Preferred Stock.
On
September 11, 2017, the Company issued an additional 210,000 shares Series B Convertible Preferred Stock to its CEO, Chaya
Hendrick, in consideration for grant of exclusive rights to the licensed patent.
As
of December 31, 2021, the Company has 5,000,000 shares of Series B Convertible Preferred Stock, par value $0.001, authorized
and 610,000 shares of Series B Convertible Preferred Stock issued and outstanding.
Holders
of the Series B Convertible Preferred Stock are entitled to receive dividends or other distributions with the holders of the common stock
of the Company on an as converted basis when, as, and if declared by the directors of the Company. Holders of the Series B Convertible
Preferred Stock are entitled to convert each share of the Series B Convertible Preferred Stock into fifty (50) shares of common stock.
Upon
any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, holders of the Series B Convertible Preferred
Stock are entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the Stated Value, pro
rata with the holders of the common stock.
Series
C Convertible Preferred Stock
From
time to time, the Company issues Series C Convertible Preferred Stock in exchange for cash. These shares are convertible into shares
of the Company’s common stock.
The
number of issued and outstanding shares of Series C Convertible Preferred Stock were 146,084 and 196,083, respectively,
for December 31, 2021 and June 30, 2021.
NOTE
6 - STOCKHOLDERS’ DEFICIT (CONTINUED)
Series
D Convertible Preferred Stock
On
July 27, 2021 the Company designated Series D Convertible Preferred Stock (the “Series D Shares”). The Series D Shares
have a stated value of $100.00 (the “Stated Value”), and carry a conversion price of the volume weighted average price (for
the 20 trading days immediate prior to the conversion date. The amount of shares of Common Stock to be issued upon any conversion shall
be calculated as the quotient of (i) the product of the issued shares of the Series D Shares to be converted and the Stated Value, and
(ii) the Conversion Price. The Series D Shares are not entitled to receive dividends or other distributions, and have no voting rights.
Common
Stock
During
the last fiscal quarter of fiscal year ending June 30, 2021, the Company increased its authorized shares of common stock from 600,000,000
to 1,200,000,000.
As
of September 30, 2021, the Company had 488,648,586 shares of common stock issued and outstanding.
|
●
|
During
the three months ended September 30, 2021, the Company sold 5,500,000 shares
of common stock for net proceeds of $27,462.
With these issuances the company also issued warrants to purchase: (i)
5,500,000 shares of common stock at a price of $0.10 per share and (ii) 5,500,000 shares of common stock at a price of $0.20 per
share. The warrants expire at various times through September 21, 2022. None of the 12,000,000 shares of common stock were
issued during the quarter ended September 30, 2021, and were recognized as stock payable.
|
|
●
|
During
the three months ended September 30, 2021, the Company issued 42,262,958 shares
of common stock, of which 8,133,333 were
issued from stock payable, 17,534,387 were
converted from 116,050 Preferred
stock and 4,095,238 shares
were issued for legal services and 12,500,000 shares
were issued as a finder’s fee.
|
As
of December 31, 2021, the Company had 539,310,756 shares of common stock issued and outstanding.
|
●
|
During the three months
ended December 31, 2021, the Company sold 8,625,000 shares
of common stock for net proceeds of $86,230.
With these issuances the Company also issued warrants to purchase: (i)
8,625,000 shares of common stock at a price of $0.70 per share and (ii) 4,312,500 shares of common stock at a price of $1.00 per
share. The warrants expire at various times through December 14, 2022. None of the 8,625,000 shares of common stock were issued
during the quarter ended December 31, 2021, and were recognized as stock payable.
|
|
●
|
During the three months
ended December 31, 2021, the Company issued 50,662,170 shares
of common stock, of which 11,032,663 were
issued from stock payable, 19,148,052 were
converted from 107,000
shares of Preferred stock, 7,981,455 shares
were issued for legal services and 12,500,000 shares
were issued as a finder’s fee to AJB Capital.
|
Equity
Financing Agreement
On
March 5, 2020, the Company entered into an equity financing agreement (the “Equity Financing Agreement”) with GHS Investments,
LLC, a Nevada limited liability company (“GHS”). Pursuant to the Equity Financing Agreement, the Company agreed to sell to
GHS an indeterminate amount of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”),
up to an aggregate price of four million dollars ($4,000,000).
NOTE
6 - STOCKHOLDERS’ DEFICIT (CONTINUED)
Following
effectiveness of the Registration Statement, the Company shall have the discretion to deliver puts to GHS and GHS will be obligated
to purchase shares of the Company’s Common Stock based on the investment amount specified in each put notice. The maximum amount
that the Company shall be entitled to put to GHS in each put notice shall not exceed two hundred percent (200%) of the average daily
trading dollar volume of the Company’s Common Stock during the ten (10) trading days preceding the put, so long as such dollar
amount does not exceed $500,000. Pursuant to the Equity Financing Agreement, GHS and its affiliates will not be permitted to purchase
and the Company may not put shares of the Company’s Common Stock to GHS that would result in GHS’s beneficial ownership,
equaling more than 4.99% of the Company’s outstanding Common Stock. The price of each put share shall be equal to eighty percent
(80%) of the Market Price (as defined in the Equity Financing Agreement). Puts may be delivered by the Company to GHS until the earlier
of thirty-six (36) months after the effectiveness of the Registration Statement.
Concurrently
with the execution of the Equity Financing Agreement, the Company entered into a convertible promissory note, for the principal balance
of $35,000. Per the terms of the convertible promissory note, the Company agreed to pay GHS interest at the rate of ten percent (10%)
until it became due on December 5, 2020. The holder of the convertible promissory note shall have the right at any time to convert all
or any part of the outstanding and unpaid principal and interest at a fixed conversion price of $0.0175. See Note 5. The principal
balance of $35,000 has been recognized as deferred financing costs in current assets on the accompanying Consolidated Balance Sheet,
and will be charged against the gross proceeds of each put when received. Although the Company has not delivered any put to GHS
yet, the Equity Financing Agreement is in effect for three (3) years, through March 2023, and as the Company does plan to put to GHS,
the Company has determined it is proper for the deferred costs to remain for the length of the Equity Financing Agreement.
Pursuant
to the Equity Financing Agreement, the Company is required, within sixty (60) calendar days upon the date of execution of the Equity
Financing Agreement, to use its best efforts to file with the SEC a registration statement or registration statements (as is necessary)
on Form S-1, covering the resale of all of the registrable securities, which registration statement(s) shall state that, in accordance
with Rule 416 promulgated under the 1933 Act, such registration statement also covers such indeterminate number of additional shares
of Common Stock as may become issuable upon stock splits, stock dividends or similar transactions. Pursuant to the Equity Financing Agreement,
the Company filed a registration statement on Form S-1 (the “Registration Statement”) on August 6, 2020. The Registration
Statement has been withdrawn as of the date of this filing and never became effective.
Warrants
From
time to time the Company granted warrants in connection with private placements of securities, as described herein.
As
of December 31, 2021, and June 30, 2021, the following is a breakdown of the warrant activity:
Schedule of share based compensation warrant activity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Range of Exercise Prices
|
|
Number of
Warrants
Outstanding
|
|
|
Weighted-
Average
Contractual Life
Remaining in Years
|
|
|
Weighted-
Average
Exercise Price
|
|
|
Number
Exercisable
|
|
|
Weighted-
Average
Exercise Price
|
|
Warrants Outstanding and Exercisable at December 31, 2021:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$0.70 - $1.00
|
|
|
69,163,518
|
|
|
|
1.24
|
|
|
$
|
0.27
|
|
|
|
69,163,518
|
|
|
$
|
0.27
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants Outstanding and Exercisable at June 30, 2021:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$0.10 - $0.20
|
|
|
124,888,519
|
|
|
|
1.12
|
|
|
$
|
0.33
|
|
|
|
124,888,519
|
|
|
$
|
0.33
|
|
NOTE
6 - STOCKHOLDERS’ DEFICIT (CONTINUED)
Warrant
Activity:
December
31, 2021:
Schedule of warrant activity
|
|
|
|
|
Outstanding - June 30, 2021
|
|
|
124,888,519
|
|
Issued
|
|
|
19,937,499
|
|
Exercised
|
|
|
—
|
|
Expired
|
|
|
(75,662,500
|
)
|
Outstanding - December 31, 2021
|
|
|
69,163,518
|
|
December
31, 2020:
Outstanding - June 30, 2020
|
|
|
53,280,406
|
|
Issued
|
|
|
66,500,000
|
|
Exercised
|
|
|
—
|
|
Expired
|
|
|
(7,610,224
|
)
|
Outstanding - December 31, 2020
|
|
|
112,170,182
|
|
At
December 31, 2021, all 69,163,518 warrants are vested and all 69,163,518 warrants expire at various times prior to December
14, 2022.
NOTE
7 - MANDATORY REDEEMABLE CONVERTIBLE PREFERRED STOCK
Issuances
of Series C Convertible Preferred Stock
On
January 10, 2019, the Board of Directors of the Company adopted a resolution pursuant to the Company’s Certificate of Incorporation,
as amended, providing for the designations, preferences and relative, participating, optional and other rights, and the qualifications,
limitations and restrictions, of the Series C Convertible Preferred Stock.
On
January 14, 2019, the Company filed a Certificate of Designations for its Series C Convertible Preferred Stock. The authorized
number of Series C Convertible Preferred Stock is 1,000,000 shares,
par value 0.001.
The Series C Convertible Preferred Stock will, with respect to dividend rights and rights upon liquidation, winding-up or
dissolution, rank: (a) senior with respect to dividends and right of liquidation with the Company’s common stock,
(b) junior with respect to dividends and right of liquidation with respect to the Company’s Series B Preferred Stock; and (c)
junior with respect to dividends and right of liquidation to all existing indebtedness of the Company. The Series C Convertible
Preferred Stock will carry an annual ten percent (10%)
cumulative dividend, compounded daily, payable solely upon redemption, liquidation or conversion. The Company will have a right, at
any time in the period of 180 days from the date of the issuance, at the Company’s option, to redeem all or any portion of the
Series C Preferred Stock at prices ranging from 105%
to 130%,
based on the passage of time.
The
number of shares of Series C Convertible Preferred Stock issued and outstanding were 146,084 and 196,084, respectively,
for December 31, 2021 and June 30, 2021.
The
holders of Series C Convertible Preferred Stock shall have the right at any time during the period beginning on the date
which is six (6) months following the date of their issuance, to convert all or any part of the outstanding Series C
Convertible Preferred Stock into fully paid and non-assessable shares of Common Stock at the Variable Conversion Price. The
“Variable Conversion Price” shall mean 71% multiplied by the Market Price (representing a discount rate of 29%).
“Market Price” means the average of the two (2) lowest Trading Prices (which means, for any security as of any date, the closing bid price
on the OTCQB, OTCQX, Pink Sheets electronic quotation system or applicable trading market (the "OTC") as reported by a reliable
reporting service ("Reporting Service") designated by the Holder (i.e. Bloomberg) for the Common Stock during the
fifteen (15) Trading Day period ending on the latest complete Trading Day prior to the date of conversion.
NOTE
7 - MANDATORY REDEEMABLE CONVERTIBLE PREFERRED STOCK (CONTINUED)
The
Series C Convertible Preferred stock is convertible after six months at 71%
of the average market price of the Company’s stock based on the lowest two (2) market closes fifteen (15) days prior.
Consequently, the shares were converted at different rates. The Company analyzed the conversion feature and determined it was
required to be bifurcated and recognized as a derivative liability. Three (3) batches of Preferred stock were subject to derivative
liability valuation based on the Black Scholes Merton pricing model. As the fair value of each of the three (3) derivative and the
shares issued at inception were in excess of the face amount of the Preferred stock, the Company recorded a discount in the amount
of $35,000
to be amortized utilizing the effective interest method of accretion over the term of the note.
On
the date which is eighteen (18) months following the Issuance Date or upon the occurrence of an Event of Default (the
“Mandatory Redemption Date”), the Company shall redeem all of the shares of Series C Convertible Preferred Stock of the
Holder (which have not been previously redeemed or converted). With five (5) days of the Mandatory Redemption Date, the Company
shall make payment to each Holder of an amount in cash equal to the total number of shares of Series C Convertible Preferred Stock
held by such Holder multiplied by the then current Stated Value.
All
shares of mandatorily redeemable convertible preferred stock have been presented outside of permanent equity in accordance with ASC 480, Classification
and Measurement of Redeemable Securities. The Company accretes the carrying value of its Series C Convertible Preferred Stock to
its estimate of fair value (i.e., redemption value) at period end.
The
carrying value of the Series C Convertible Preferred Stock at December 31, 2021 and June 30, 2021 was $146,084 and
$196,083 net
of discount, respectively. There
were 96,250 shares of Series C Preferred Stock issued for net proceeds of $80,000, and 107,000 shares of Series C Preferred Stock
converted to 19,148,092 shares of Common Stock for the three months ended December 31, 2021.
NOTE
8 - DERIVATIVE LIABILITIES
The
conversion rates of the convertible notes and Series C Convertible Preferred Stock are convertible at a variable rate. Accordingly, the
Company concluded there is an embedded derivative which was required to be bifurcated and accounted for as a derivative liability. The
Company chose to use the Black Scholes model to calculate the derivative liability. The assumptions in the derivative liability calculation
included the price of the Company’s common stock of $0.0141 at the valuation date, term of zero, a risk free rate of between
$0.0010 and $0.0011 and a volatility rate of between 150% and 341%. The Company has recorded the embedded derivative liability
at its’ fair value utilizing the Black-Scholes Merton option pricing model, as follows:
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Total
|
|
Derivative liability
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
476,075
|
|
|
$
|
476,075
|
|
NOTE
9 - INCOME TAXES
The
Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year.
Cumulative adjustments to the Company’s estimate are recorded in the interim period in which a change in the estimated annual effective
rate is determined.
The
Company has estimated its effective tax rate to be 0%, based primarily on losses incurred and the uncertainty of realization of
the tax benefit of such losses.
NOTE
10 - SUBSEQUENT EVENTS
In
accordance with ASC 855-10, the Company has reviewed its operations subsequent to December 31, 2021 to the date these financial statements
were issued. Between January 1, 2022 and February 11, 2022, other than as described in “Recent Developments” in Part
I, Item 2 of this Quarterly Report, there were no subsequent events.